{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:44:14Z","timestamp":1782895454054,"version":"3.54.5"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The accelerated approval of sonrotoclax makes it the first BCL-2 inhibitor cleared for relapsed or refractory mantle cell lymphoma, offering a mechanistically distinct option for patients who have tried BTK inhibitor therapy. The drug, which binds BCL-2 with more than 10-fold greater potency than venetoclax and may carry a cleaner platelet toxicity profile, is now being tested head-to-head against venetoclax in multiple phase III chronic lymphocytic leukemia trials that could reshape the treatment landscape for that disease as well.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2026-0056","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:04:41Z","timestamp":1779375881000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2026,5,21]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NW2026-0056\/785368\/First-BCL-2-Inhibitor-Approved-for-Mantle-Cell","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/7\/OF1\/786234\/First-BCL-2-Inhibitor-Approved-for-Mantle-Cell","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/7\/OF1\/786234\/First-BCL-2-Inhibitor-Approved-for-Mantle-Cell","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:53:19Z","timestamp":1782892399000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/7\/OF1\/786234\/First-BCL-2-Inhibitor-Approved-for-Mantle-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2026-0056","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}